

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents

P.O. Box 1459

Alexandria, Virginia 22313-1450

or Fax (703) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE, if required. Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, Advance Order, and notification of issuance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by e-mail specifying a new correspondence address; and/or (in indicating a separate "FEE ADDRESS" for issuance fee notifications).

CHARGE CORRESPONDENCE/MAILING: In Block 1 for my charge of mailing:

20147

7599

000150009

GLAXOSMITHKLINE
CORPORATE INTELLECTUAL PROPERTY, MAIL 1459
FIVE MOORE DR., PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) transmittal. This certificate of mailing may be used for any other accompanying papers. Each additional page, such as an assignment or formal drawing, must have its own certificate of mailing or transmittal.

Certificate of Mailing or Transmittal

I hereby certify that the **Fee(s) Transmittal** is being deposited with the United States Postal Service as **first class postage paid** and will be mailed to the address indicated to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (703) 273-2885, on the day indicated below:

(Dated and signed)
(Signed)
(Date)

APPLICATION #/D	FILING DATE	PRIORITY NAME/INITIALS	ATTORNEY DOCKET NO.	CINERFATIN 100
30551-358	04/14/2005	Rachel Andiff	PAULINEW	5642

TITLE OF INVENTION: SUBSTITUTED PIPERAZINES (1A) DIAZEPINES, AND 2,5- DIAZABICYCLO (2.2.1)HEPTANE AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H2 REVERSE ANTAGONISTS

APPLN. TYPE	SMALL ENTITY	PRIORITY DATE	IN THE COUNTRY (CITY, STATE)	PAYER	PAID DUE (MM)	TOTAL PAID (DOLLARS)	DAYS LATE
nonprovisional	NO	31510	\$300	\$0	\$180	00/15/05-09	

EXAMINER	ART. UNIT	CLASS-Subclass
CHEZMAN, BRIANNA LIBBY	1626	114-239000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.36):

Change of correspondence address for Change of Correspondence Address from PTO 1459-223-002.

"Fee Address" indication for "Fee Address" Indication form (37 CFR 1.36, Box 1459-223-002 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patient front page, list:

(1) the names of up to 3 registered patent attorneys or agents OR

(2) the name of a single firm having as a member a registered attorney or agent and the names of up to 2 other registered patent attorneys or agent. If no name is listed, no name will be printed.

1. *James P. Riek*

2. _____

3. _____

3. ASSIGNEE NAME AND RESIDENCE/ DATA TO BE PRINTED ON THE PATENT (print or type):

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.14. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE (CITY AND STATE OR COUNTRY)

Glaxo Group Limited

Greenford, Middlesex, United Kingdom

Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government

4a. The following fees are submitted:

Issue fee

Publication Fee (\$6 small entity also not permitted)

Advance Order - # of Copies _____ 2

4b. Payment of Fees: Please first remit any previously paid issue fee shown above.

A check is enclosed.

Payment by credit card. Form PTO 2036 is attached.

The Director is hereby authorized to charge the required fees, any deficiency, or credit any overpayment, to Deposit Account Number 571-132-322 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above):

I/We am claiming SMALL ENTITY status. See 37 CFR 1.27.

I/We am no longer claiming SMALL ENTITY status. See 37 CFR 1.27(e)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attorney or agent, or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature:


James P. Riek

Type or print name:

Date: 15 Sept 2009

Registration No. 39,009

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is guaranteed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1459, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.